AJOVista LLC Takes Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AJOVista LLC acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 163 shares of the biopharmaceutical company’s stock, valued at approximately $143,000.

Other institutional investors have also recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. increased its stake in Regeneron Pharmaceuticals by 135.8% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 10,126 shares of the biopharmaceutical company’s stock worth $8,333,000 after acquiring an additional 5,832 shares during the period. Raymond James Financial Services Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 0.5% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 8,391 shares of the biopharmaceutical company’s stock valued at $6,905,000 after purchasing an additional 42 shares in the last quarter. Stratos Wealth Partners LTD. lifted its position in Regeneron Pharmaceuticals by 29.4% during the third quarter. Stratos Wealth Partners LTD. now owns 466 shares of the biopharmaceutical company’s stock worth $383,000 after purchasing an additional 106 shares during the period. NorthRock Partners LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $205,000. Finally, Forsta AP Fonden grew its stake in Regeneron Pharmaceuticals by 1.0% during the third quarter. Forsta AP Fonden now owns 20,500 shares of the biopharmaceutical company’s stock worth $16,871,000 after buying an additional 200 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 2.1 %

REGN stock traded up $19.39 during mid-day trading on Friday, reaching $957.00. The company’s stock had a trading volume of 547,373 shares, compared to its average volume of 509,442. Regeneron Pharmaceuticals, Inc. has a 12 month low of $684.80 and a 12 month high of $998.33. The company has a current ratio of 6.40, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The business’s 50 day moving average price is $943.75 and its 200 day moving average price is $896.33. The company has a market cap of $105.04 billion, a price-to-earnings ratio of 28.27, a price-to-earnings-growth ratio of 2.69 and a beta of 0.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to analyst estimates of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $10.96 EPS. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.86 EPS for the current year.

Insiders Place Their Bets

In other news, EVP Marion Mccourt sold 1,000 shares of the stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the sale, the director now owns 18,282 shares in the company, valued at approximately $17,953,838.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Marion Mccourt sold 1,000 shares of the company’s stock in a transaction on Monday, February 5th. The stock was sold at an average price of $934.71, for a total transaction of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares in the company, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,095 shares of company stock worth $9,664,476. 8.83% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on REGN shares. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $925.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday. UBS Group raised their target price on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Barclays upped their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Finally, Truist Financial reissued a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $977.77.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.